Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, ...

One thing that we're seeing is lung cancers being diagnosed earlier and earlier, whereas, historically, 75% of lung cancers ...

Roche’s data on Wednesday come from the Phase III lidERA Breast Cancer study, which assessed the adjuvant use of giredestrant ...

Patients with stage 1 or 2, hormone receptor (HR)-negative breast cancer had similar five-year rates of locoregional ...

Dr Hope Rugo explores how new data suggest immunotherapy could reshape the standard of care for early-stage HR+ and ...

Lumpectomy has been the standard of care for low-risk, early-stage breast cancer, but now cryoablation — freezing cancer ...

Today at the San Antonio Breast Cancer Symposium (SABCS), researchers presented the initial findings from a major multi-year collaboration between the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and ...

Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first ...

Prostate cancer can be difficult to detect in its beginning stages — here's what to look out for Getty Prostate cancer is one of the most common types of cancer in males. It starts in the prostate, a ...

Justin Stebbing does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...